Guoqian Venture Capital

Guoqian Venture Capital, founded in 2017 and based in Suzhou, China, specializes in early and middle-stage investments in the medical devices sector. The firm aims to support the growth of start-ups within the medical devices, in vitro diagnostic reagents, and biotechnology industries, aligning with its strategic objective of integrating industry with capital. Through its focused investment approach, Guoqian Venture Capital seeks to foster innovation and development in critical areas of healthcare technology.

Chen Hao

Partner

13 past transactions

Jiangsu Junhua

Venture Round in 2024
Jiangsu Junhua is an engineering plastics manufacturer specializing in the research and development of high-performance special engineering plastic parts and profiles like PEEK and PI.

Insaifeiying

Seed Round in 2024
Insaifeiying is a manufacturer of innovative medical equipment for minimally invasive surgery. It focuses on the research, development, and manufacturing of intelligent wireless endoscopes.

Yunmao Technology

Series B in 2023
Yunmao Technology is a specialized manufacturer of nanotechnology equipment, focusing on ultra-high vacuum coating equipment, atomic layer deposition systems, and ion beam etching systems. The company serves a diverse range of sectors, including semiconductor production, chip manufacturing, and lithium battery development. By providing advanced solutions for thin film deposition, Yunmao Technology aims to meet the needs of enterprises in the pan-semiconductor and new energy industries, ensuring high-quality standards and innovative applications in nanotechnology.

BioAntibody

Series A in 2023
BioAntibody is a biotechnology company focused on the research and development of antigens, antibodies, and downstream detection reagents for diagnostic and therapeutic applications. The firm specializes in creating core raw materials intended for in vitro diagnostics and biopharmaceuticals. Utilizing innovative high-efficiency targeted hybridoma cell fusion technology, BioAntibody supports stable cell growth and high-throughput screening across various medical categories, including cardiovascular, cerebrovascular, inflammation, infectious diseases, tumors, and hormones. By providing high-quality raw materials, the company aims to enhance disease detection and improve therapeutic outcomes for its customers.

Baikang Bio

Series A in 2023
Baikang Bio is a tech biotechnology firm specializing in the research and development of antigens, antibodies, and downstream detection reagents for diagnosis and therapy. The product pipelines cover cardiovascular and cerebrovascular, inflammation, infectious diseases, tumors, hormones, and other categories, from raw materials to finished goods. They are dedicated to innovation and providing their customers with solutions. They could contribute to human ecology and health.

Nenstar Electronic Technology

Venture Round in 2022
Leanstar Sensor has developed the core design capabilities of multi-variety and multi-range flexible micro-nano mechanical force sensors. Their products are flexible pressure sensors, flexible piezoelectric sensors, flexible capacitive sensors, flexible thermal sensors, flexible temperature and humidity sensors, and flexible integrated composite micro-nano sensors.

Keyto

Series B in 2021
Keyto specializes in the production of key electrical and mechanical components for microfluid system controls.

magAssist

Series B in 2021
magAssist, founded in 2017 by Dr. Xu Bozhen, is a high-tech enterprise based in Suzhou, specializing in the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular diseases. The company focuses on creating short-term to medium-term ventricular assist devices that are compatible with various blood types. Utilizing advanced fluid mechanics and magnetic suspension technology, magAssist aims to minimize incompatibility issues in patients, thereby enhancing their recovery and treatment processes. The core team consists of leading experts in artificial heart engineering, leveraging extensive experience in research and development to produce domestically manufactured devices with independent intellectual property rights.

Dima Biotech

Angel Round in 2019
Dima Biotech is a tumor immunotherapy and monoclonal antibody developer, specializing in the development of recombinant monoclonal antibodies for tumor immune products and services. It has the unique RECmAb digital monoclonal antibody technology, which can be used to obtain a variety of genus and high quality. Monoclonal antibodies.

magAssist

Series A in 2019
magAssist, founded in 2017 by Dr. Xu Bozhen, is a high-tech enterprise based in Suzhou, specializing in the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular diseases. The company focuses on creating short-term to medium-term ventricular assist devices that are compatible with various blood types. Utilizing advanced fluid mechanics and magnetic suspension technology, magAssist aims to minimize incompatibility issues in patients, thereby enhancing their recovery and treatment processes. The core team consists of leading experts in artificial heart engineering, leveraging extensive experience in research and development to produce domestically manufactured devices with independent intellectual property rights.

Guoke Junhao

Seed Round in 2019
Guoke Junhao is a POCT medical device and diagnostic reagent research and development distributor, focusing on the field of chemiluminescence immunoassay, mainly developing small automatic microfluidic immunoassay analyzer, which can realize inspection automation, fast and efficient, low cost, simple operation, etc.

EYESEE Medical

Angel Round in 2017
EYESEE Medical is a provider of comprehensive ophthalmology services, specializing in eye screening and eye care for children, teens, and adults. The company operates a chain of clinics that offer vision screenings and behavioral awareness education. EYESEE Medical has developed a myopia prevention and control strategy tailored to individual needs, establishing eye health records to monitor and predict the onset and progression of myopia in young populations. Additionally, the company has implemented an artificial intelligence system designed for visual acuity screening, enhancing the accuracy and efficiency of eye care services. Through its innovative approach, EYESEE Medical aims to improve vision health outcomes across various age groups.

APOLLOMICS

Angel Round in 2015
APOLLOMICS is a biotechnology company that develops domestic clinical testing reagents and provides disease testing services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.